{"success":true,"data":{"pressRelease":{"id":"112493","rtpr_id":"nPn6c8Mta","ticker":"7733","exchange":"TSE Tokyo","all_tickers":["7733"],"title":"Olympus Reports First Quarter Fiscal 2027 Financial Results","author":"PR Newswire","published_at":"2026-08-07T07:00:03.427Z","article_body":"Olympus Reports First Quarter Fiscal 2027 Financial Results\n\nPR Newswire\n\nTOKYO, Aug. 7, 2026\n\n Strong GIS Growth and Margin Expansion Support Full-Year Guidance\n\nTOKYO, Aug. 7, 2026 /PRNewswire/ -- Olympus Corporation (Olympus), a global\nMedTech company committed to advancing endoscopy-enabled care, today reported\nfirst quarter fiscal 2027 results for the three months ended June 30, 2026.\nFirst quarter revenue was 240.4 billion Japanese yen, up 16% year on year and\nup 5% in constant currency. Strong momentum in the Gastrointestinal Solutions\n(GIS) business drove growth. While the Surgical and Interventional Solutions\n(SIS) business was affected by voluntary ship holds, core franchises Urology\nand Respiratory delivered revenue growth. Olympus maintains the full-year\nFY2027 guidance provided in May 2026.\n\nFirst Quarter Key Highlights\n\n * Revenue of ¥240.4 billion, up 16% year on year (up 5% in constant currency)\n * GIS revenue of ¥168.4 billion, up 21% year on year (up 10% in constant\ncurrency)\n * SIS revenue of ¥71.9 billion, up 7% year on year (down 4% in constant\ncurrency)\n * Adjusted operating profit of ¥30.7 billion, up 133% year on year; adjusted\noperating margin of 12.8%, up 6.4 percentage points year on year\n * Adjusted EPS of ¥20, up 130% year on year\nFirst Quarter Financial Results\n\nOn a consolidated basis, revenue was ¥240.4 billion, up 16% year on year and\nup 5% in constant currency, with this increase also aided by a comparatively\nlow prior-year base.\n\nContinued double-digit growth in GIS across Olympus' core markets,\nparticularly in North America, Europe, and APAC, was the primary driver, with\nGIS revenue reaching ¥168.4 billion, up 21% year on year. North America\ndelivered a strong quarter, reflecting continued customer demand supported by\nstrong sales execution. This growth offset an approximately ¥13 billion\ntemporary revenue headwind, primarily in SIS, related to ship holds and\nFDA-related import alerts. Excluding this temporary impact, the underlying\nbusiness delivered a strong start to the year.\n\nSIS revenue was ¥71.9 billion, up 7% year on year. Despite the impact of\nvoluntary ship holds and FDA-related import alerts, SIS continued to benefit\nfrom strong demand. This was driven by the strength of the product portfolio,\nparticularly with the continued growth in the core franchises of Urology and\nRespiratory, which improved 14% and 15% year on year, respectively. On a\nconstant currency basis, SIS revenue declined 4% due to the temporary impact\nof voluntary ship holds and FDA-related import alerts. The majority of\nship-hold-affected products are expected to resume shipment in the second half\nof this fiscal year.\n\nAdjusted operating profit was ¥30.7 billion, up 133% year on year, with\nadjusted operating margin of 12.8%, an increase of 6.4 percentage points year\non year (5.7 percentage points in constant currency). This improvement was\ndriven by strong GIS revenue growth, an 8.9 percentage point improvement to\n23.3% in GIS adjusted operating margin, and lower SG&A reflecting R&D\nexpenditure timing and personnel expense savings from the position\noptimization program.\n\nAdjusted EPS was ¥20, up 130% year on year.\n\nQuality Assurance and Regulatory Update\n\nOlympus is continuing its constructive engagement with the FDA and the\nimplementation of its quality remediation program. The FDA has not yet issued\na classification for the inspections conducted last fall. Olympus will\ncontinue to cooperate fully with the FDA and assess any feedback or\nclassification once received. The majority of ship-hold-affected products are\nexpected to resume shipment in the second half of FY2027, consistent with the\nassumption embedded in the full-year guidance. The full-year guidance\ncontinues to incorporate the company's current assumptions regarding quality\nremediation activities and associated expenditures.\n\nAs previously announced, effective August 1, 2026, Brian Barry assumed the\nrole of Chief Quality Officer and will lead the next phase of Olympus' efforts\nto further strengthen quality systems and the quality culture across the\norganization.\n\nFY2027 Guidance\n\nOlympus maintains the full-year FY2027 guidance provided in May 2026. The\nstrong first-quarter performance is consistent with the assumptions underlying\nthe company's full-year guidance.\n\nThe company continues to expect structural tailwinds in the second half of the\nyear, including the anticipated normalization of ship-hold-related impacts,\nthe contribution from new product launches, and the scaling of efficiency\ngains. These drivers underpin the company's expectations for the remainder of\nthe year and support its confidence in delivering on its full-year guidance\ncommitments.\n\n\"We experienced a solid start to the year, with continued execution across our\nkey markets and growth aided by lower prior-year comparisons,\" said Michael\nParenti, Executive Officer and Chief Financial Officer of Olympus. \"This\nconfirms that we are building momentum. While it remains early in the year,\nour first-quarter performance and expected second-half tailwinds support our\nconfidence in maintaining our current full-year guidance. We will provide a\nfurther update as second-half visibility improves.\"\n\nFirst-quarter FY 2027 financial results materials are available here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4747911-1&h=228421977&u=https%3A%2F%2Fwww.olympus-global.com%2Fir%2Fdata%2Fbrief%2F2027.html%3Fpage%3Dir&a=here)\n.\n\nAbout Olympus\n\nAt Olympus, we are committed to Our Purpose of making people's lives\nhealthier, safer and more fulfilling. As a global medical technology company,\nwe partner with healthcare professionals to provide innovative solutions and\nservices for early detection, diagnosis and minimally invasive treatment,\naiming to improve patient outcomes by elevating the standard of care in\ntargeted disease states.\n\nFor more than 100 years, Olympus has pursued a goal of contributing to society\nby producing products designed with the purpose of delivering optimal outcomes\nfor its customers around the world. For more information, visit the Olympus\nwebsite\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4747911-1&h=330545223&u=https%3A%2F%2Fwww.olympus-global.com%2F&a=Olympus+website)\n and follow the Olympus LinkedIn account\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4747911-1&h=109926490&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Folympus-corp%2Fposts%2F%3FfeedView%3Dall&a=the+Olympus+LinkedIn+account)\n.\n\nThis material contains forward-looking statements that reflect management's\ncurrent views, plans, and expectations based on information available at the\ntime of preparation. These forward-looking statements are not guarantees of\nfuture performance and involve known and unknown risks, uncertainties, future\nbusiness decisions, and other internal and external factors that may cause the\nCompany's actual results, performance, achievements, or financial position to\nbe materially different from any future results expressed or implied by these\nforward-looking statements.\n\nAll trademarks, logos and brand names are the property of their respective\nowners.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/olympus-reports-first-quarter-fiscal-2027-financial-results-302845896.html\n(https://www.prnewswire.com/news-releases/olympus-reports-first-quarter-fiscal-2027-financial-results-302845896.html)\n\nSOURCE Olympus Corporation\n\n\n\nLeslie James, Olympus Corporation, Email: Global-Public_Relations@olympus.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS606144/Olympus-Logo.jpg?id=OA2834436\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn6c8Mta","title":"Olympus Reports First Quarter Fiscal 2027 Financial Results","author":"PR Newswire","ticker":"7733","created":"2026-08-07T07:00:03.427Z","tickers":["7733"],"exchange":"TSE Tokyo","article_body":"Olympus Reports First Quarter Fiscal 2027 Financial Results\n\nPR Newswire\n\nTOKYO, Aug. 7, 2026\n\n Strong GIS Growth and Margin Expansion Support Full-Year Guidance\n\nTOKYO, Aug. 7, 2026 /PRNewswire/ -- Olympus Corporation (Olympus), a global\nMedTech company committed to advancing endoscopy-enabled care, today reported\nfirst quarter fiscal 2027 results for the three months ended June 30, 2026.\nFirst quarter revenue was 240.4 billion Japanese yen, up 16% year on year and\nup 5% in constant currency. Strong momentum in the Gastrointestinal Solutions\n(GIS) business drove growth. While the Surgical and Interventional Solutions\n(SIS) business was affected by voluntary ship holds, core franchises Urology\nand Respiratory delivered revenue growth. Olympus maintains the full-year\nFY2027 guidance provided in May 2026.\n\nFirst Quarter Key Highlights\n\n * Revenue of ¥240.4 billion, up 16% year on year (up 5% in constant currency)\n * GIS revenue of ¥168.4 billion, up 21% year on year (up 10% in constant\ncurrency)\n * SIS revenue of ¥71.9 billion, up 7% year on year (down 4% in constant\ncurrency)\n * Adjusted operating profit of ¥30.7 billion, up 133% year on year; adjusted\noperating margin of 12.8%, up 6.4 percentage points year on year\n * Adjusted EPS of ¥20, up 130% year on year\nFirst Quarter Financial Results\n\nOn a consolidated basis, revenue was ¥240.4 billion, up 16% year on year and\nup 5% in constant currency, with this increase also aided by a comparatively\nlow prior-year base.\n\nContinued double-digit growth in GIS across Olympus' core markets,\nparticularly in North America, Europe, and APAC, was the primary driver, with\nGIS revenue reaching ¥168.4 billion, up 21% year on year. North America\ndelivered a strong quarter, reflecting continued customer demand supported by\nstrong sales execution. This growth offset an approximately ¥13 billion\ntemporary revenue headwind, primarily in SIS, related to ship holds and\nFDA-related import alerts. Excluding this temporary impact, the underlying\nbusiness delivered a strong start to the year.\n\nSIS revenue was ¥71.9 billion, up 7% year on year. Despite the impact of\nvoluntary ship holds and FDA-related import alerts, SIS continued to benefit\nfrom strong demand. This was driven by the strength of the product portfolio,\nparticularly with the continued growth in the core franchises of Urology and\nRespiratory, which improved 14% and 15% year on year, respectively. On a\nconstant currency basis, SIS revenue declined 4% due to the temporary impact\nof voluntary ship holds and FDA-related import alerts. The majority of\nship-hold-affected products are expected to resume shipment in the second half\nof this fiscal year.\n\nAdjusted operating profit was ¥30.7 billion, up 133% year on year, with\nadjusted operating margin of 12.8%, an increase of 6.4 percentage points year\non year (5.7 percentage points in constant currency). This improvement was\ndriven by strong GIS revenue growth, an 8.9 percentage point improvement to\n23.3% in GIS adjusted operating margin, and lower SG&A reflecting R&D\nexpenditure timing and personnel expense savings from the position\noptimization program.\n\nAdjusted EPS was ¥20, up 130% year on year.\n\nQuality Assurance and Regulatory Update\n\nOlympus is continuing its constructive engagement with the FDA and the\nimplementation of its quality remediation program. The FDA has not yet issued\na classification for the inspections conducted last fall. Olympus will\ncontinue to cooperate fully with the FDA and assess any feedback or\nclassification once received. The majority of ship-hold-affected products are\nexpected to resume shipment in the second half of FY2027, consistent with the\nassumption embedded in the full-year guidance. The full-year guidance\ncontinues to incorporate the company's current assumptions regarding quality\nremediation activities and associated expenditures.\n\nAs previously announced, effective August 1, 2026, Brian Barry assumed the\nrole of Chief Quality Officer and will lead the next phase of Olympus' efforts\nto further strengthen quality systems and the quality culture across the\norganization.\n\nFY2027 Guidance\n\nOlympus maintains the full-year FY2027 guidance provided in May 2026. The\nstrong first-quarter performance is consistent with the assumptions underlying\nthe company's full-year guidance.\n\nThe company continues to expect structural tailwinds in the second half of the\nyear, including the anticipated normalization of ship-hold-related impacts,\nthe contribution from new product launches, and the scaling of efficiency\ngains. These drivers underpin the company's expectations for the remainder of\nthe year and support its confidence in delivering on its full-year guidance\ncommitments.\n\n\"We experienced a solid start to the year, with continued execution across our\nkey markets and growth aided by lower prior-year comparisons,\" said Michael\nParenti, Executive Officer and Chief Financial Officer of Olympus. \"This\nconfirms that we are building momentum. While it remains early in the year,\nour first-quarter performance and expected second-half tailwinds support our\nconfidence in maintaining our current full-year guidance. We will provide a\nfurther update as second-half visibility improves.\"\n\nFirst-quarter FY 2027 financial results materials are available here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4747911-1&h=228421977&u=https%3A%2F%2Fwww.olympus-global.com%2Fir%2Fdata%2Fbrief%2F2027.html%3Fpage%3Dir&a=here)\n.\n\nAbout Olympus\n\nAt Olympus, we are committed to Our Purpose of making people's lives\nhealthier, safer and more fulfilling. As a global medical technology company,\nwe partner with healthcare professionals to provide innovative solutions and\nservices for early detection, diagnosis and minimally invasive treatment,\naiming to improve patient outcomes by elevating the standard of care in\ntargeted disease states.\n\nFor more than 100 years, Olympus has pursued a goal of contributing to society\nby producing products designed with the purpose of delivering optimal outcomes\nfor its customers around the world. For more information, visit the Olympus\nwebsite\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4747911-1&h=330545223&u=https%3A%2F%2Fwww.olympus-global.com%2F&a=Olympus+website)\n and follow the Olympus LinkedIn account\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4747911-1&h=109926490&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Folympus-corp%2Fposts%2F%3FfeedView%3Dall&a=the+Olympus+LinkedIn+account)\n.\n\nThis material contains forward-looking statements that reflect management's\ncurrent views, plans, and expectations based on information available at the\ntime of preparation. These forward-looking statements are not guarantees of\nfuture performance and involve known and unknown risks, uncertainties, future\nbusiness decisions, and other internal and external factors that may cause the\nCompany's actual results, performance, achievements, or financial position to\nbe materially different from any future results expressed or implied by these\nforward-looking statements.\n\nAll trademarks, logos and brand names are the property of their respective\nowners.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/olympus-reports-first-quarter-fiscal-2027-financial-results-302845896.html\n(https://www.prnewswire.com/news-releases/olympus-reports-first-quarter-fiscal-2027-financial-results-302845896.html)\n\nSOURCE Olympus Corporation\n\n\n\nLeslie James, Olympus Corporation, Email: Global-Public_Relations@olympus.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS606144/Olympus-Logo.jpg?id=OA2834436\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-07T07:00:03.498206941Z","server_sent_at_ms":1786086003498},"received_at":"2026-08-07T07:00:03.555Z","source_url":"https://www.prnewswire.com/news-releases/olympus-reports-first-quarter-fiscal-2027-financial-results-302845896.html"},"analysis":{"id":"101497","press_release_id":"112493","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Voluntary ship holds and FDA-related import alerts affecting SIS revenue","FDA has not yet issued a classification for inspections conducted last fall"],"eventType":"earnings","narrative":"Olympus reported strong Q1 fiscal 2027 results with revenue rising 16% year on year to ¥240.4 billion, while adjusted operating profit surged 133% driven by margin expansion.\n\nThe Gastrointestinal Solutions (GIS) segment led growth with a 21% revenue increase, offsetting a ¥13 billion headwind in Surgical and Interventional Solutions (SIS) due to voluntary ship holds and FDA import alerts.\n\nManagement maintained its full-year FY2027 guidance, expressing confidence that the strong start and expected normalization of shipment impacts in the second half will support annual targets.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Q1 profit doubles on strong GIS growth; Olympus keeps FY guidance despite FDA headwinds."},"keyFigures":{"eps":"¥20","revenue":"¥240.4 billion","guidance":"Maintains full-year FY2027 guidance provided in May 2026","revenueYoy":"16%","customDimensions":{"gis_revenue":"¥168.4 billion","sis_revenue":"¥71.9 billion","adj_operating_margin":"12.8%","adj_operating_profit":"¥30.7 billion","adj_operating_profit_yoy":"133%"}},"quotedText":"We experienced a solid start to the year, with continued execution across our key markets and growth aided by lower prior-year comparisons","namedEntities":{"people":[{"name":"Michael Parenti","role":"Executive Officer and Chief Financial Officer"},{"name":"Brian Barry","role":"Chief Quality Officer"}],"products":["Gastrointestinal Solutions (GIS)","Surgical and Interventional Solutions (SIS)"],"companies":[{"name":"Olympus Corporation","ticker":"7733"}],"dollarAmounts":[{"amount":"¥240.4 billion","context":"First quarter revenue"},{"amount":"¥168.4 billion","context":"GIS revenue"},{"amount":"¥71.9 billion","context":"SIS revenue"},{"amount":"¥30.7 billion","context":"Adjusted operating profit"},{"amount":"¥13 billion","context":"Temporary revenue headwind in SIS"}]},"materialImpact":{"score":4,"reasoning":"Strong operational performance with 16% revenue growth and 133% growth in adjusted operating profit, alongside significant margin expansion of 6.4 percentage points. The company maintained full-year guidance despite temporary FDA-related headwinds."},"tickerRelevance":{"others":[],"primary":"7733"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":["guidance_update"],"importanceComponents":{"tickerTier":"Large-cap Global","eventGravity":"Strong earnings with margin expansion","sectorWeight":"MedTech"}},"event_type":"earnings","event_type_secondary":["guidance_update"],"sentiment":"bullish","material_impact_score":4,"narrative":"Olympus reported strong Q1 fiscal 2027 results with revenue rising 16% year on year to ¥240.4 billion, while adjusted operating profit surged 133% driven by margin expansion.\n\nThe Gastrointestinal Solutions (GIS) segment led growth with a 21% revenue increase, offsetting a ¥13 billion headwind in Surgical and Interventional Solutions (SIS) due to voluntary ship holds and FDA import alerts.\n\nManagement maintained its full-year FY2027 guidance, expressing confidence that the strong start and expected normalization of shipment impacts in the second half will support annual targets.","key_figures":{"eps":"¥20","revenue":"¥240.4 billion","guidance":"Maintains full-year FY2027 guidance provided in May 2026","revenueYoy":"16%","customDimensions":{"gis_revenue":"¥168.4 billion","sis_revenue":"¥71.9 billion","adj_operating_margin":"12.8%","adj_operating_profit":"¥30.7 billion","adj_operating_profit_yoy":"133%"}},"named_entities":{"people":[{"name":"Michael Parenti","role":"Executive Officer and Chief Financial Officer"},{"name":"Brian Barry","role":"Chief Quality Officer"}],"products":["Gastrointestinal Solutions (GIS)","Surgical and Interventional Solutions (SIS)"],"companies":[{"name":"Olympus Corporation","ticker":"7733"}],"dollarAmounts":[{"amount":"¥240.4 billion","context":"First quarter revenue"},{"amount":"¥168.4 billion","context":"GIS revenue"},{"amount":"¥71.9 billion","context":"SIS revenue"},{"amount":"¥30.7 billion","context":"Adjusted operating profit"},{"amount":"¥13 billion","context":"Temporary revenue headwind in SIS"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-07T11:38:28.953Z","global_importance":45,"audience_relevance":35,"importance_components":{"tickerTier":"Large-cap Global","eventGravity":"Strong earnings with margin expansion","sectorWeight":"MedTech"}},"durationMs":252212,"modelName":"glm-4.7"}}